论文部分内容阅读
目的:观察和胃消痞合剂对慢性胃炎大鼠胃炎pH值以及血液超氧岐化酶(SOD)、丙二醛(MDA)含量的影响。方法:SD大鼠74只,12只为正常对照组(A组),其余参与综合法造模,处死2只大鼠确认造模成功,然后参与造模的大鼠随机分成5组,分别为空白对照组(B组12只)、阳性对照组(C组12只)、和胃消痞合剂低剂量组(D组12只)、和胃消痞合剂(E组12只)、和胃消痞合剂高剂量组(F组12只)。造模完成后,B组给予蒸馏水灌胃,C组给予三九胃泰冲剂灌胃,D、E、F组分别给予和胃消痞合剂低、中、高剂量药液灌胃,1月后处死动物。然后测定大鼠血液的SOD和MDA值和胃液的pH值。结果:A、B、C、D、E、F组的SOD值分别为173 310U/L、158 670U/L、173 050U/L、174 190U/L、172 390U/L、170 550U/L,与B组比较,A、C、D、E、F组SOD活力升高非常明显(P<0.01);A、B、C、D、E、F组的MDA值分别为8.03nmol/mL、9.79nmol/mL、7.93nmol/mL、8.32nmol/mL、7.50nmol/mL,与B组相比,A、C、E、F组MDA明显降低(P<0.05);D、E、F组间的pH值、SOD值、MDA值没有明显差别。结论:和胃消痞合剂对慢性胃炎大鼠具有一定治疗作用,提高大鼠血液SOD的活力,减少MDA含量是其机制之一。
Objective: To observe the effect of Weixiaopi mixture on the gastritis pH and the content of blood superoxide dismutase (SOD) and malondialdehyde (MDA) in rats with chronic gastritis. Methods: Thirty-four Sprague-Dawley rats were randomly divided into five groups: control group (A group), control group (12 rats) and model control group The control group (12 rats in group B), the positive control group (12 rats in group C), the low dose group (12 rats in group D) and Weixiaopisan mixture (12 rats in group E) Buwei mixture of high-dose group (F group 12). After modeling, group B was administered with distilled water, Group C was given Sanjiowitai Granule, Group D, E, F were treated with low, medium and high dose of Weixiapisan mixture and gavage respectively. After 1 month Animals were sacrificed. Then determine the rat blood SOD and MDA values and gastric pH value. Results: The SOD values in groups A, B, C, D, E and F were 173 310U / L, 158 670U / L, 173 050U / L, 174 190U / L, 172 390U / L and 170 550U / The MDA of A, B, C, D, E and F groups were 8.03nmol / mL and 9.79nmol respectively in group A, C, D, E and F / mL, 7.93nmol / mL, 8.32nmol / mL and 7.50nmol / mL respectively. Compared with group B, MDA in groups A, C, E and F decreased significantly (P < Value, SOD value, MDA value no significant difference. Conclusion: Hewei Xiaopi mixture has a certain therapeutic effect on rats with chronic gastritis, and it is one of the mechanisms to improve the activity of SOD and reduce the content of MDA in rat blood.